IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Exclusion Criteria

• •1. Participants with isolated intraocular PCNSL or spinal PCNSL with no brain lesions
• •2. Participants with non-B-cell PCNSL
• •3. Participants with systemic presence of lymphoma
• •4. Refractory to temozolomide with or without rituximab-containing regimens in the last PCNSL treatment
• •5. Concomitant systemic corticosteroid exposure within 14 days before starting study drug per Investigator assessment with the exception of the following:
• •* Equivalent of up to 10 milligram per day (mg/day) of prednisone for a disease other than PCNSL
• •* Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day dexamethasone) for participants with lesions of the brain and/or spinal cord
• •6. Active malignancy, other than PCNSL requiring systemic therapy
• •7. Poorly controlled comorbidity, or history of medical conditions contraindicated per Investigator assessment
• •8. Participants who are unable to swallow oral medication
• •9. Prior Bruton's tyrosine kinase inhibitor treatment